Coccidioidomycosis future or investigational therapies: Difference between revisions
No edit summary |
m Bot: Removing from Primary care |
||
| (4 intermediate revisions by 3 users not shown) | |||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
The major focus has been the development of a defined, T-cell-reactive, recombinant protein vaccine.Cole GT et al in 2008 described the first genetically engineered, live, attenuated vaccine that protects both BALB/c and C57BL/6 mice against coccidioidomycosis. Two chitinase genes (CTS2 and CTS3) were disrupted to yield the attenuated strain, which was unable to endosporulate and was no longer infectious. Vaccinated survivors mounted an immune response characterized by production of both T-helper-1- and T-helper-2-type cytokines. Histology revealed well-formed granulomas and markedly diminished inflammation. Significantly fewer organisms were observed in the lungs of survivors than in those of nonvaccinated mice. However futher research is needed before we adapt these models to human beings.<ref name="Xue-2009">{{Cite journal | last1 = Xue | first1 = J. | last2 = Chen | first2 = X. | last3 = Selby | first3 = D. | last4 = Hung | first4 = CY. | last5 = Yu | first5 = JJ. | last6 = Cole | first6 = GT. | title = A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. | journal = Infect Immun | volume = 77 | issue = 8 | pages = 3196-208 | The major focus has been the development of a defined, T-cell-reactive, recombinant protein vaccine. Cole GT et al in 2008 described the first genetically engineered, live, attenuated vaccine that protects both BALB/c and C57BL/6 mice against coccidioidomycosis. Two chitinase genes (CTS2 and CTS3) were disrupted to yield the attenuated strain, which was unable to endosporulate and was no longer infectious. Vaccinated survivors mounted an immune response characterized by production of both T-helper-1- and T-helper-2-type cytokines. Histology revealed well-formed granulomas and markedly diminished inflammation. Significantly fewer organisms were observed in the lungs of survivors than in those of nonvaccinated mice. However futher research is needed before we adapt these models to human beings.<ref name="Xue-2009">{{Cite journal | last1 = Xue | first1 = J. | last2 = Chen | first2 = X. | last3 = Selby | first3 = D. | last4 = Hung | first4 = CY. | last5 = Yu | first5 = JJ. | last6 = Cole | first6 = GT. | title = A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. | journal = Infect Immun | volume = 77 | issue = 8 | pages = 3196-208 | doi = 10.1128/IAI.00459-09 | PMID = 19487479 }}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Fungal diseases]] | [[Category:Fungal diseases]] | ||
[[Category:Biological weapons]] | [[Category:Biological weapons]] | ||
[[Category:Disease]] | |||
[[Category:Emergency medicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
Latest revision as of 21:00, 29 July 2020
|
Coccidioidomycosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Coccidioidomycosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Coccidioidomycosis future or investigational therapies |
|
FDA on Coccidioidomycosis future or investigational therapies |
|
CDC on Coccidioidomycosis future or investigational therapies |
|
Coccidioidomycosis future or investigational therapies in the news |
|
Blogs on Coccidioidomycosis future or investigational therapies |
|
Risk calculators and risk factors for Coccidioidomycosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Vidit Bhargava, M.B.B.S [2]
Overview
The major focus has been the development of a defined, T-cell-reactive, recombinant protein vaccine. Cole GT et al in 2008 described the first genetically engineered, live, attenuated vaccine that protects both BALB/c and C57BL/6 mice against coccidioidomycosis. Two chitinase genes (CTS2 and CTS3) were disrupted to yield the attenuated strain, which was unable to endosporulate and was no longer infectious. Vaccinated survivors mounted an immune response characterized by production of both T-helper-1- and T-helper-2-type cytokines. Histology revealed well-formed granulomas and markedly diminished inflammation. Significantly fewer organisms were observed in the lungs of survivors than in those of nonvaccinated mice. However futher research is needed before we adapt these models to human beings.[1]
References
- ↑ Xue, J.; Chen, X.; Selby, D.; Hung, CY.; Yu, JJ.; Cole, GT. "A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis". Infect Immun. 77 (8): 3196–208. doi:10.1128/IAI.00459-09. PMID 19487479.